Alberto Villalobos - Colección de Propiedad Industrial e Intelectual (Vol. 4)

“[…] Claim 20. The method of claim 19 wherein the patient suffers from an autoimmune disease selected from the group consisting of acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti– GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal and neuronal neuropathies, Behcet’s disease, bullous pemphigoid, autoimmune cardiomyopathy, Castleman disease, celiac disease, Chagas disease, […]”

Compounds

WO2017025416A1

Abstract

A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Espacenet Url

http://v3.espacenet.com/publicationDetails/biblio?KC=A1&CC=WO&NR=2017025416&FT=E&DB=EPODOC&locale=en_EP

Gamma secretase modulators for the treatment of immune system dysfunction.

WO2017019496A1

Abstract

The present invention provides methods of treating an immune system dysfunction or conditions associated with soluble BCMA using gamma secretase modulators or inhibitors in order to both restore immune function and improve the efficacy of therapies directed against BCMA present on the pathogenic B cell.

Espacenet Url

http://v3.espacenet.com/publicationDetails/biblio?KC=A1&CC=WO&NR=2017019496&FT=E&DB=EPODOC&locale=en_EP

Claims

CLAIMS What is claimed is: 1. A method of treating or preventing an immune system dysfunction in a subject comprising administering to the subject one or more gamma secretase modulators or a derivative thereof. 2. A method of decreasing BCMA shedding from a plasma cell comprising administering one or more gamma secretase modulators or a derivative thereof to a subject having an immune system dysfunction, optionally wherein the immune system dysfunction is due to the expression of BCMA. 3. A method of increasing the efficacy of a therapy in a subject being treated for a B cell condition or disorder comprising: administering the subject one or more gamma secretase modulators or a derivative thereof in addition to the existing treatment being provided to the subject. 4. The method of claim 1 or claim 2, wherein the immune system dysfunction is a B cell condition or disorder. 5. The method of any one of claims 2-4, wherein the B cell condition or disorder is selected from the group consisting of: MM, WM, CLL, B cell non-Hodgkin’s lymphoma, plasmacytoma, Hodgkins’ lymphoma, follicular lymphomas, small non-cleaved cell lymphomas, endemic Burkitt’s lymphoma, sporadic Burkitt’s lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodal monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, small lymphocytic lymphoma, B cell proliferations of uncertain malignant potential, lymphomatoidgranulomatosis, post-transplant lymphoproliferative disorder, an immunoregulatory disorder, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chagas’ disease, […]”.

Il-26 inhibitors

WO2017009392A1

Abstract

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.

Espacenet Url

http://v3.espacenet.com/publicationDetails/biblio?KC=A1&CC=WO&NR=2017009392&FT=E&DB=EPODOC&locale=en_EP

Anti-trypanosomal compounds and methods

WO2017004215A1

Abstract

Triterpenoidiridals and derivatives thereof have anti-trypanosomal activity.

Espacenet Url

http://v3.espacenet.com/publicationDetails/biblio?KC=A1&CC=WO&NR=2017004215&FT=E&DB=EPODOC&locale=en_EP

Los Códigos de Clasificación Cooperativa de patentes (CPC) analizadas, muestran la tendencia sobre qué innovaciones están creciendo más y podrían ser candidatas para hacer más pruebas. Así por ejemplo, en el año 2016, se publicaron nueve patentes en la clasificación C07D487/00 - asignada por la Oficina Europea de Patentes (EPO)– Compuestos heterocíclicos que contienen átomos de nitrógeno como únicos heteroátomos del ciclo en el sistema condensado.

Como ya se mencionó, por medio de las bases de dato de libre acceso, se pueden obtener tanto los datos bibliográficos de los documentos de patentes publicados, como el documento completo de cada patente. A modo de ejemplo, incluimos los datos bibliográficos de una de las nueve patentes publicadas antes referidas.

P2x7 modulators

US2016039836A1

Abstract

The present invention is directed to a compound of Formula (I): wherein: The present invention is directed to a compound of Formula (I): wherein: n is an integer from 0-1; X is CH2 when n is 0, or X is CH2 or oxygen when n is 1; R1 is phenyl or pyridinyl, wherein the phenyl or pyridinyl is optionally substituted with from 1 to 4 substituents independently selected from halogen and alkyl; and R2 is S phenyl, pyridinyl, pyrazinyl, pyradizinyl, pyrimidinyl, pyrrolyl, pyrazolyl, thiazolyl or thiophenyl, wherein the phenyl, pyridinyl, pyrazinyl, pyradizinyl, pyrimidinyl, pyrrolyl, pyrazolyl, thiazolyl or thiophenyl is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halogen, alkyl, hydroxy and alkoxy. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). The compounds of formula (I) are useful as P2X7 modulators.